Laurent Pharmaceuticals Provides Clinical Development Update
MONTREAL, April 8, 2021 /CNW Telbec/ - Laurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing first-in-class pro-resolving drug LAU-7b, today announces that the independent Data Safety Monitoring Board (DSMB) for the Phase 2 RESOLUTION study in hospitalized patients with COVID-19 unanimously recommended to continue the study without modification following a pre-scheduled safety review and mid-study interim futility analysis of unblinded efficacy data from the first 102 patients treated in the study. The company also reports the completion of enrollment in its Phase 2 APPLAUD study in adult patients with Cystic Fibrosis (CF).